Take a look through some of the notable data presentations at this year's ESMO Congress.
|Videos|December 7, 2021
Dr. Armstrong on the efficacy of AR inhibitors in men with oligometastatic prostate cancer
Author(s)Urology Times staff
“Our data suggests that we shouldn’t just be relying on metastasis-directed therapy alone,” says Andrew J. Armstrong, MD, MSc.
Advertisement
In this video, Andrew J. Armstrong, MD, MSc, discusses the takeaways and further research associated with the study, “The efficacy of enzalutamide (Enza) plus androgen deprivation therapy (ADT) on oligometastatic hormone-sensitive prostate cancer: extended post hoc analysis of ARCHES,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Armstrong is a profession or medicine, surgery, and pharmacology and cancer biology at Duke University and a member of the Duke Cancer in Durham, North Carolina.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Engy Habashy, MD, on the role of androgens in GSM management
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5